A probiotic composition for improving mammary gland and preparation method thereof

By developing a probiotic composition to improve the breast, the side effects and drug resistance problems in the treatment and prevention of mastitis in the prior art have been solved, safe and effective prevention and treatment of mastitis and improved the body's immunity.

CN118104829BActive Publication Date: 2024-11-29GROYOU (GUANGZHOU) BIOTECHNOLOGY CO LTD
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202410195669.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-22
Publication Date
2024-11-29
Estimated Expiration
2044-02-22

AI Technical Summary

Technical Problem

The prior art has side effects, drug resistance problems in the treatment and prevention of mastitis, and lacks effective prevention and treatment methods. Especially for pregnant women and lactating women, there is insufficient safe and no side effects.

Method used

Develop a probiotic composition to improve the breast, and prepare a probiotic composition with antioxidant, anti-inflammatory and antibacterial effects through specific raw material ratios and preparation methods, for the prevention, treatment and auxiliary treatment of mastitis, and improve Body immunity.

Benefits of technology

This probiotic composition can effectively prevent and treat mastitis, reduce the occurrence of breast nodules, improve immunity, and has broad application prospects, and reduce the damage of pathogenic bacteria to the breast by improving the balance of intestinal microbial flora.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_5
    Figure SMS_5
  • Figure SMS_6
    Figure SMS_6
  • Figure SMS_7
    Figure SMS_7
Patent Text Reader

Abstract

The present invention proposes a probiotic composition for improving mammary gland and a preparation method thereof, and belongs to the technical field of probiotics. Prepared by the following raw materials by weight: oligomaltose, erythritol, oligofructose, oligogalactose, red raspberry juice powder, inactive edible yeast, fermented lactobacillus LC40, Lactobacillus paracasei Lpc‑37, Lactobacillus acidophilus NCFM, Bifidobacterium animalis lactis subspecies Bb‑12, Lactobacillus rhamnosus GG, seaweed powder, citric acid. The probiotic composition prepared by the present invention and the probiotic composition preparation method for improving mammary gland are simple, the raw material source is wide, the cost is low, and the obtained composition has good antioxidant, anti-inflammatory, antibacterial and other effects, can prevent, treat, and assist in the treatment of mastitis, prevent and treat breast nodules, improve body immunity, and have broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of probiotics, and in particular to a probiotic composition for improving mammary glands and a preparation method thereof. Background Art

[0002] A variety of factors can cause our bodies to become imbalanced.

[0003] Mastitis is an inflammation of the breast tissue, which can be classified as subclinical or clinical depending on the degree of inflammation. Mastitis can occur at any time during lactation. It is particularly common during the second and third weeks postpartum. Subclinical mastitis (SCM) is an inflammatory condition of the lactating breast that is understood to be caused by milk stagnation and / or infection and is associated with an increased risk of lactation failure and inadequate infant weight gain. Staphylococcal infections, particularly those of S. aureus and S. epidermidis, are understood to be the main causes of mastitis.

[0004] Current treatment of mastitis typically involves the administration of antibiotics. However, the widespread use of antibiotics presents several challenges, including ineffectiveness due to antibiotic resistance, the development of multi-antibiotic resistant bacterial strains, biofilm formation, vaginal candidiasis, and antibiotic-associated diarrhea. Furthermore, it has been shown that there is insufficient evidence to support the effectiveness of antibiotic therapy for the treatment of lactational mastitis. Therefore, improved methods for the treatment and prevention of mastitis are greatly needed.

[0005] A safe solution for the prevention and treatment of mastitis without side effects is needed, especially in groups that are vulnerable or unable to tolerate medical interventions, such as pregnant or lactating women. Summary of the invention

[0006] The purpose of the present invention is to provide a probiotic composition for improving breast and a preparation method thereof. The preparation method is simple, the raw material source is wide, and the cost is low. The prepared composition has good antioxidant, anti-inflammatory, antibacterial and other effects, can prevent, treat, and assist in the treatment of mastitis, prevent and treat breast nodules, and improve the body's immunity, and has broad application prospects.

[0007] The technical solution of the present invention is achieved in this way:

[0008] The invention provides a probiotic composition. The probiotic composition is prepared from the following raw materials in parts by weight: 3-4 parts of isomaltooligosaccharide, 2-3 parts of erythritol, 6-8 parts of fructooligosaccharide, 3-5 parts of galacto-oligosaccharide, 0.1-0.3 parts of red raspberry juice powder, 0.2-0.7 parts of inactive edible yeast, 0.1-0.5 parts of fermented lactobacillus LC40, 0.1-0.2 parts of lactobacillus paracasei Lpc-37, 0.05-0.15 parts of lactobacillus acidophilus NCFM, 0.01-0.1 parts of bifidobacterium animalis subspecies lactis Bb-12, 0.02-0.1 parts of lactobacillus rhamnosus GG, 0.1-0.3 parts of seaweed powder and 0.1-0.2 parts of citric acid.

[0009] As a further improvement of the present invention, the viable bacteria content of the fermented Lactobacillus LC40 is 2-4 billion cfu / g, the viable bacteria content of the Lactobacillus paracasei Lpc-37 is 6-8 billion cfu / g, the viable bacteria content of the Lactobacillus acidophilus NCFM is 1-3 billion cfu / g, the viable bacteria content of the Bifidobacterium animalis subspecies lactis Bb-12 is 1-3 billion cfu / g, and the viable bacteria content of the Lactobacillus rhamnosus GG is 1-3 billion cfu / g.

[0010] The present invention further protects the use of the above-mentioned probiotic composition in preparing products for preventing and treating mastitis.

[0011] The present invention further protects a method for preparing a probiotic composition for improving mammary glands, comprising the following steps:

[0012] S1. Extraction of active components of propolis: adding propolis to a low eutectic solvent containing water, extracting by ultrasonic heating, filtering, retaining the solid, and separating and purifying the filtrate with a macroporous resin to obtain active components of propolis;

[0013] S2. Extraction of active polysaccharides: Wash, dry, and crush the astragalus, loofah, and dandelion to obtain a powder, add it to water, heat and boil it for extraction, filter it, and retain the residue. Add ethanol to the filtrate for precipitation, filter it, wash the solid, and dry it to obtain active polysaccharides;

[0014] S3. Preparation of active polysaccharide-Zn / Cu chelate: adding the active polysaccharide obtained in step S2 to water, adding zinc salt and copper salt, heating and stirring to react, dialyzing, and drying the dialyzate to obtain an active polysaccharide-Zn / Cu chelate;

[0015] S4. Fermentation: The solid in step S1, the filter residue in step S2, and the prebiotics are added to water, sterilized, inoculated with Lactobacillus fermentum LC40 and Lactobacillus paracasei Lpc-37 seed solution, fermented, filtered, the solid is washed with sterile water, the eluate is collected, concentrated, a concentrated bacterial solution is obtained, and the liquid is freeze-dried to obtain a fermentation product;

[0016] S5. Preparation of a probiotic composition for improving mammary glands: adding the active polysaccharide-Zn / Cu chelate and sodium alginate obtained in step S3 to the concentrated bacterial solution obtained in step S4, adding Lactobacillus acidophilus NCFM, Bifidobacterium animalis lactis subsp. Bb-12, and Lactobacillus rhamnosus GG to obtain an aqueous phase, adding the aqueous phase to soybean oil, adding lecithin, emulsifying, adding a calcium chloride solution dropwise, solidifying at room temperature, centrifuging, washing, and drying to obtain microcapsules, and uniformly mixing the microcapsules with melatonin, seaweed powder, the fermentation product obtained in step S4, and the propolis active component obtained in step S1 to obtain a probiotic composition for improving mammary glands.

[0017] As a further improvement of the present invention, the low eutectic solvent in step S1 is a mixture of choline chloride and glucose in a molar ratio of 1:1, the water content in the low eutectic solvent containing water is 40-50wt%, the mass ratio of the propolis and the low eutectic solvent containing water is 1:3-5, the power of the ultrasonic heating extraction is 1000-2000W, the heating temperature is 45-55°C, and the time is 1-3h. The macroporous resin is selected from at least one of AB-8, LX-218, XDA-6, D-101, LX-T28 or LX-26. The separation and purification method is to fill the resin to a resin column with a diameter-to-height ratio of 1:5-10, a sample load of 15-25BV, and an adsorption flow rate of 5-7BV / h; after the adsorption is completed, eluted with 3-7BV deionized water, and then eluted with 30-50wt% ethanol solution, the eluate is collected, and dried to obtain a product.

[0018] As a further improvement of the present invention, the mass ratio of astragalus, loofah and dandelion in step S2 is 3-5:7-10:2-4, the solid-liquid ratio of the powder and water is 1:5-10 g / mL, the heating and boiling extraction time is 3-5h, the ethanol content of the system is added to 70-80wt%, and the precipitation time is 5-7h.

[0019] As a further improvement of the present invention, the mass ratio of the active polysaccharide, the zinc salt and the copper salt in step S3 is 10-20:1-2:0.1-0.2, the zinc salt is selected from at least one of zinc chloride, zinc sulfate, zinc nitrate and zinc citrate, the copper salt is selected from at least one of copper chloride, copper sulfate and copper nitrate, the temperature of the heating and stirring reaction is 40-50°C, the time is 0.5-1h, the pore size of the dialysis bag used for dialysis is 500-1000Da, and the dialysis time is 2-4h.

[0020] As a further improvement of the present invention, the mass ratio of the solid in step S1, the filter residue in step S2, the prebiotics and the water in step S4 is 5-7:12-15:3-5:200-400, the prebiotics are selected from at least one of isomaltooligosaccharide, erythritol, oligofructose and oligogalactose, the inoculation amounts of the fermented Lactobacillus LC40 and the Lactobacillus paracasei Lpc-37 strain seed liquids are 2-4 v / v% and 1-2 v / v%, respectively, and the bacterial contents of the fermented Lactobacillus LC40 and the Lactobacillus paracasei Lpc-37 strain seed liquids are both 10 8 -10 10 cfu / mL, the fermentation culture conditions are 35-38°C, 100-150r / min, fermentation culture 36-48h, the bacterial content of the concentrated bacterial solution is 10 10 -10 11 cfu / mL.

[0021] As a further improvement of the present invention, the mass ratio of the active polysaccharide-Zn / Cu chelate, sodium alginate, concentrated bacterial solution, Lactobacillus acidophilus NCFM, Bifidobacterium animalis lactis subspecies Bb-12, Lactobacillus rhamnosus GG, and lecithin in step S5 is 10-12:15-20:100-150:2-5:3-6:1-2:2-3, and the mass ratio of the microcapsule, melatonin, seaweed powder, fermentation product, and propolis active component is 15-20:0.5-1:2-4:3-5:2-4.

[0022] The present invention further protects a probiotic composition for improving mammary glands prepared by the above preparation method.

[0023] The present invention has the following beneficial effects:

[0024] The probiotic composition of the present invention contains rich prebiotic components, which can provide rich nutrients for the proliferation and development of probiotics, so as to better play the physiological effects of probiotics; the fermented lactobacillus LC40 (CECT5716) in the probiotic composition of the present invention is derived from healthy human breast milk, and its safety is approved by the US FDA and the EU EFSA, and can treat mastitis, prevent and treat breast nodules; Lactobacillus paracasei Lpc-37 can improve emotional problems, relieve anxiety and stress; among other probiotics, lactobacillus and bifidobacterium can help enhance the estrogen metabolome to metabolize excess estrogen, and can reduce the symptoms caused by hormone imbalance. Its main principle is to improve estrogen metabolism by reducing the activity of β-glucuronidase. In addition to the above effects, the probiotic composition of the present invention can also effectively balance the intestinal flora, improve immunity, and thus reduce the damage of other pathogens to the breast.

[0025] The seaweed powder added in the present invention is rich in vitamin D3, which can support the health of breast cell DNA and protect cells from free radical damage; at the same time, it can inhibit fibrocystic breast changes and reduce the risk of cancer.

[0026] The probiotic composition for improving mammary gland of the present invention uses propolis as a raw material, and extracts by ultrasonic-assisted low eutectic co-solvent, thereby significantly improving the extraction rate of flavonoid components in propolis, wherein the flavonoid components include quercetin, myricetin, luteolin, naringenin, etc. Quercetin has multiple biological activities, such as anti-inflammatory, antioxidant, anti-cancer, etc., and can inhibit the expression of proinflammatory cytokines by regulating multiple signal pathways such as PI3K / AKT, mTOR, NF-κB, MAPK, JAK / STAT, Nrf2, etc., thereby achieving the effect of relieving mastitis; the parent ring structure of myricetin contains more hydroxyl groups than other flavonoids, and relative to other flavonoids such as quercetin, it exhibits stronger pharmacological activities such as antioxidant, anti-inflammatory, and antibacterial, and inhibits the activation of NF-κB and STAT1, thereby downregulating the level of HO-1 mediated by Nrf2, thereby inhibiting the expression of proinflammatory cytokines. Luteolin can relieve inflammatory responses in many ways, such as reducing the production of reactive oxygen species, regulating multiple signaling pathways such as NF-κB, MAPK, and JAK / STAT, affecting the metabolism of arachidonic acid, and inhibiting the expression of inflammatory factors. Naringenin has multiple pharmacological effects such as antiviral, antibacterial, anti-inflammatory, antioxidant, and anti-cancer. It reduces the production of inflammatory mediators by affecting the HIF-1 signaling pathway, and then obtains a high-purity flavonoid composition under the separation and purification of macroporous resin.

[0027] Astragalus has the effects of invigorating qi, promoting blood circulation and removing blood stasis; Luffa has the effects of dredge meridians, promoting blood circulation and dispelling wind; Taraxacum has the effects of reducing swelling, dispersing knots and sterilizing, and can treat breast hyperplasia and relieve symptoms of mastitis; At the same time, Astragalus, Luffa and Taraxacum are rich in active components such as polysaccharides, wherein the polysaccharide component has good antibacterial and anti-inflammatory effects, and at the same time, it contains rich structures such as hydroxyl groups, which can form complexes with metal ions, and the addition of zinc can significantly improve the body's immunity and improve the resistance to pathogenic bacteria; The addition of copper can improve antibacterial and antioxidant abilities, thereby inhibiting inflammation caused by pathogenic bacteria, and improving the body's antioxidant ability, and the two have a synergistic effect. In addition, the active polysaccharide-Zn / Cu chelate prepared by the present invention and sodium alginate can form a polysaccharide microcapsule shell under the cross-linking effect of calcium ions, have good gastric acid resistance and choline resistance effects, can well protect probiotics from entering the intestinal colonization and play a better effect of preventing, treating and assisting the treatment of mastitis.

[0028] The present invention uses solid residues extracted from propolis and solid residues obtained from polysaccharides extracted from astragalus, loofah and dandelion as raw materials, adds prebiotics, and inoculates lactobacillus fermentum LC40 and lactobacillus paracasei Lpc-37 for fermentation, which can not only promote the proliferation of probiotics, but also inhibit the growth activity of pathogenic bacteria through competitive growth with pathogenic bacteria in the intestinal tract through anti-inflammatory factors such as interleukin-10 and transforming growth factor-β secreted by probiotics after fermentation, and significantly improve inflammation. Secondary metabolites such as bacteriocins, organic acids and hydrogen peroxide produced in its metabolic process can also inhibit or kill pathogenic bacteria.

[0029] The melatonin added in the present invention can pass through the cell membrane and act on various organelles, and has multiple physiological functions such as anti-stress, anti-inflammation, sleep promotion, mood improvement, reproduction regulation and immunity enhancement. Its metabolites are also effective antioxidants and free radical scavengers, and can absorb active oxygen through the 5-methoxy group on its own indole ring, convert it into non-oxidative substances, play an antioxidant role, inhibit the expression and activation of NF-κB through nuclear receptors, prevent it from transferring to the cell nucleus and binding to DNA, and activate the DNA repair mechanism, reduce the synthesis of inflammatory mediators, and regulate the expression of inflammatory factors, thereby reducing the degree of inflammatory response.

[0030] The probiotic composition prepared by the present invention and the probiotic composition for improving mammary glands have simple preparation methods, wide sources of raw materials and low costs. The prepared composition has good antioxidant, anti-inflammatory and antibacterial effects, can prevent, treat and assist in the treatment of mastitis, prevent and treat breast nodules, and improve the body's immunity, and has broad application prospects. DETAILED DESCRIPTION

[0031] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0032] Lactobacillus fermentum (CECT5716) produced by Biosearch Life, Spain, 3 billion cfu / g.

[0033] Lactobacillus paracasei Produced by DuPont-Danisco (DANISCO) of the United States, 7 billion cfu / g.

[0034] Lactobacillus acidophilus 2 billion cfu / g, Bifidobacterium animalis subsp. lactis Bb-122 billion cfu / g, Lactobacillus rhamnosus GG 2 billion cfu / g, produced by DuPont-Danisco (DANISCO) of the United States;

[0035] Inactive edible yeast Inactive edible yeast.

[0036] Seaweed powder is produced by Protec Nutra in the UK.

[0037] The preparation method of the seed liquid of Lactobacillus fermentum LC40 and Lactobacillus paracasei Lpc-37 is as follows: Lactobacillus fermentum LC40 and Lactobacillus paracasei Lpc-37 are inoculated into Gao's medium respectively, and the culture is activated at 37°C and 100 r / min for 18 hours to obtain the seed liquid, the bacterial content of which is 10 8 -10 9 cfu / mL.

[0038] Example 1

[0039] The present embodiment provides a probiotic composition, comprising 3 parts by weight of isomaltooligosaccharide, 2 parts by weight of erythritol, 6 parts by weight of fructooligosaccharide, 3 parts by weight of galacto-oligosaccharide, 0.1 parts by weight of red raspberry juice powder, 0.2 parts by weight of inactive edible yeast, 0.1 parts by weight of fermented Lactobacillus LC40, 0.1 parts by weight of Lactobacillus paracasei Lpc-37, 0.05 parts by weight of Lactobacillus acidophilus NCFM, 0.01 parts by weight of Bifidobacterium animalis subsp. lactis Bb-12, 0.02 parts by weight of Lactobacillus rhamnosus GG, 0.1 parts by weight of seaweed powder, and 0.1 parts by weight of citric acid, which are stirred and mixed for 30 minutes to prepare a probiotic composition.

[0040] Example 2

[0041] The present embodiment provides a probiotic composition, comprising 4 parts by weight of isomaltooligosaccharide, 3 parts by weight of erythritol, 8 parts by weight of fructooligosaccharide, 5 parts by weight of galacto-oligosaccharide, 0.3 parts by weight of red raspberry juice powder, 0.7 parts by weight of inactive edible yeast, 0.5 parts by weight of Lactobacillus fermentum LC40, 0.2 parts by weight of Lactobacillus paracasei Lpc-37, 0.15 parts by weight of Lactobacillus acidophilus NCFM, 0.1 parts by weight of Bifidobacterium animalis subsp. lactis Bb-12, 0.1 parts by weight of Lactobacillus rhamnosus GG, 0.3 parts by weight of seaweed powder, and 0.2 parts by weight of citric acid, which are stirred and mixed for 30 minutes to prepare a probiotic composition.

[0042] Example 3

[0043] The present embodiment provides a probiotic composition, comprising 3.6 parts by weight of isomaltooligosaccharide, 2.3 parts by weight of erythritol, 7.8 parts by weight of fructooligosaccharide, 4.6 parts by weight of galacto-oligosaccharide, 0.2 parts by weight of red raspberry juice powder, 0.5 parts by weight of inactive edible yeast, 0.3 parts by weight of Lactobacillus fermentum LC40, 0.175 parts by weight of Lactobacillus paracasei Lpc-37, 0.1 parts by weight of Lactobacillus acidophilus NCFM, 0.04 parts by weight of Bifidobacterium animalis subsp. lactis Bb-12, 0.058 parts by weight of Lactobacillus rhamnosus GG, 0.2 parts by weight of seaweed powder, and 0.127 parts by weight of citric acid, which are stirred and mixed for 30 minutes to prepare a probiotic composition.

[0044] Example 4

[0045] This embodiment provides a method for preparing a probiotic composition for improving mammary glands, comprising the following steps:

[0046] S1. Extraction of active components of propolis: add 10 parts by weight of propolis to 30 parts by weight of a low eutectic solvent containing water, heat to 45°C with 1000W ultrasonic wave, extract for 1h, filter, retain the solid, use macroporous resin D-101 for the filtrate, fill the resin to a resin column with a diameter-to-height ratio of 1:5, load 15BV, adsorption flow rate 5BV / h; after adsorption, elute with 3BV of deionized water, then elute with 40wt% ethanol solution, collect the eluate, dry, and obtain the active components of propolis;

[0047] The low eutectic solvent is a mixture of choline chloride and glucose, with a molar ratio of 1:1; the water content in the low eutectic solvent containing water is 40wt%;

[0048] S2. Extraction of active polysaccharides: 3 parts by weight of Astragalus, 7 parts by weight of Luffa, and 2 parts by weight of Taraxacum were washed, dried, and crushed to obtain a powder, which was added to water at a solid-liquid ratio of 1:5 g / mL. The mixture was heated and boiled for extraction for 3 h, filtered, and the residue was retained. Ethanol was added to the filtrate until the ethanol content of the system was 70 wt%, and the mixture was precipitated for 5 h, filtered, the solid was washed, and dried to obtain an active polysaccharide.

[0049] S3. Preparation of active polysaccharide-Zn / Cu chelate: 10 parts by weight of the active polysaccharide obtained in step S2 was added to 200 parts by weight of water, 1 part by weight of zinc sulfate and 0.1 part by weight of copper sulfate were added, heated to 40°C, stirred for 0.5h, dialyzed for 2h using a dialysis bag with a pore size of 500Da, and the dialyzate was dried to obtain an active polysaccharide-Zn / Cu chelate;

[0050] S4. Fermentation: 5 parts by weight of the solid in step S1, 12 parts by weight of the filter residue in step S2, and 3 parts by weight of prebiotics were added to 200 parts by weight of water, sterilized, inoculated with Lactobacillus fermentum LC40 and Lactobacillus paracasei Lpc-37 seed solution, the inoculation amounts were 2v / v% and 1v / v%, respectively, at 35°C, 100r / min, fermented and cultured for 36h, filtered, the solid was washed with sterile water, the eluate was collected, concentrated, and a bacterial count of 10 10 -10 11 cfu / mL of concentrated bacterial liquid, and freeze-dried the liquid to obtain the fermentation product;

[0051] S5. Preparation of a probiotic composition for improving mammary glands: 10 parts by weight of the active polysaccharide-Zn / Cu chelate prepared in step S3 and 15 parts by weight of sodium alginate are added to 100 parts by weight of the concentrated bacterial solution prepared in step S4, 2 parts by weight of Lactobacillus acidophilus NCFM, 3 parts by weight of Bifidobacterium animalis subspecies lactis Bb-12, and 1 part by weight of Lactobacillus rhamnosus GG are added to obtain an aqueous phase, the aqueous phase is added to 500 parts by weight of soybean oil, 2 parts by weight of lecithin are added, emulsified at 7000 r / min for 15 minutes, 5 parts by weight of 3wt% calcium chloride solution are added dropwise, solidified at room temperature for 20 minutes, centrifuged, washed, and dried to obtain microcapsules, 15 parts by weight of microcapsules are mixed with 0.5 parts by weight of melatonin, 2 parts by weight of seaweed powder, 3 parts by weight of the fermentation product prepared in step S4, and 2 parts by weight of the propolis active component prepared in step S1, and stirred and mixed for 20 minutes to obtain a probiotic composition for improving mammary glands.

[0052] Example 5

[0053] This embodiment provides a method for preparing a probiotic composition for improving mammary glands, comprising the following steps:

[0054] S1. Extraction of active components of propolis: 10 parts by weight of propolis was added to 50 parts by weight of a low eutectic solvent containing water, and the mixture was heated to 55°C with 2000W ultrasonic wave, and the mixture was extracted for 3 hours, filtered, and the solid was retained. The filtrate was filled with macroporous resin D-101, and the resin was filled to a resin column with a diameter-to-height ratio of 1:10. The sample loading was 25BV, and the adsorption flow rate was 7BV / h. After the adsorption was completed, the mixture was eluted with 7BV of deionized water, and then with 40wt% ethanol solution. The eluate was collected and dried to obtain the active components of propolis.

[0055] The low eutectic solvent is a mixture of choline chloride and glucose, with a molar ratio of 1:1; the water content in the low eutectic solvent containing water is 50wt%;

[0056] S2. Extraction of active polysaccharides: 5 parts by weight of Astragalus, 10 parts by weight of Luffa, and 4 parts by weight of Taraxacum were washed, dried, and crushed to obtain a powder, which was added to water at a solid-liquid ratio of 1:10 g / mL. The mixture was heated and boiled for extraction for 5 h, filtered, and the residue was retained. Ethanol was added to the filtrate until the ethanol content of the system was 80 wt %, and the mixture was precipitated for 7 h, filtered, the solid was washed, and dried to obtain an active polysaccharide.

[0057] S3. Preparation of active polysaccharide-Zn / Cu chelate: 20 parts by weight of the active polysaccharide obtained in step S2 was added to 200 parts by weight of water, 2 parts by weight of zinc nitrate and 0.2 parts by weight of copper nitrate were added, heated to 50°C, stirred for 1 hour, dialyzed for 4 hours using a dialysis bag with a pore size of 1000Da, and the dialyzate was dried to obtain an active polysaccharide-Zn / Cu chelate;

[0058] S4. Fermentation: 7 parts by weight of the solid in step S1, 15 parts by weight of the filter residue in step S2, and 5 parts by weight of prebiotics were added to 400 parts by weight of water, sterilized, inoculated with Lactobacillus fermentum LC40 and Lactobacillus paracasei Lpc-37 seed solution, the inoculation amount was 4v / v% and 2v / v%, respectively, at 38°C, 150r / min, fermented and cultured for 48h, filtered, the solid was washed with sterile water, the eluate was collected, concentrated, and a bacterial count of 10 10 -10 11 cfu / mL of concentrated bacterial liquid, and freeze-dried the liquid to obtain the fermentation product;

[0059] S5. Preparation of a probiotic composition for improving mammary glands: 12 parts by weight of the active polysaccharide-Zn / Cu chelate prepared in step S3 and 20 parts by weight of sodium alginate are added to 150 parts by weight of the concentrated bacterial solution prepared in step S4, 5 parts by weight of Lactobacillus acidophilus NCFM, 6 parts by weight of Bifidobacterium animalis subspecies lactis Bb-12, and 2 parts by weight of Lactobacillus rhamnosus GG are added to obtain an aqueous phase, the aqueous phase is added to 500 parts by weight of soybean oil, 3 parts by weight of lecithin are added, emulsified at 7000 r / min for 15 minutes, 10 parts by weight of 5wt% calcium chloride solution is added dropwise, solidified at room temperature for 30 minutes, centrifuged, washed, and dried to obtain microcapsules, 20 parts by weight of microcapsules are mixed with 1 part by weight of melatonin, 4 parts by weight of seaweed powder, 5 parts by weight of the fermentation product prepared in step S4, and 4 parts by weight of the propolis active component prepared in step S1, and stirred and mixed for 20 minutes to obtain a probiotic composition for improving mammary glands.

[0060] Example 6

[0061] This embodiment provides a method for preparing a probiotic composition for improving mammary glands, comprising the following steps:

[0062] S1. Extraction of active components of propolis: add 10 parts by weight of propolis to 40 parts by weight of a low eutectic solvent containing water, heat to 50°C with 1500W ultrasonic wave, extract for 2h, filter, retain the solid, use macroporous resin D-101 for the filtrate, fill the resin to a resin column with a diameter-to-height ratio of 1:7, load 20BV, adsorption flow rate 6BV / h; after adsorption, elute with 5BV of deionized water, then elute with 40wt% ethanol solution, collect the eluate, dry, and obtain active components of propolis;

[0063] The low eutectic solvent is a mixture of choline chloride and glucose, with a molar ratio of 1:1; the water content in the low eutectic solvent containing water is 45wt%;

[0064] S2. Extraction of active polysaccharides: 4 parts by weight of Astragalus, 8 parts by weight of Luffa, and 3 parts by weight of Taraxacum were washed, dried, and crushed to obtain powder, which was added to water. The solid-liquid ratio of the powder to water was 1:7 g / mL. The mixture was heated and boiled for 4 h, filtered, and the residue was retained. Ethanol was added to the filtrate until the ethanol content of the system was 75 wt%, and the mixture was precipitated for 6 h. The mixture was filtered, the solid was washed, and dried to obtain active polysaccharides.

[0065] S3. Preparation of active polysaccharide-Zn / Cu chelate: 15 parts by weight of the active polysaccharide obtained in step S2 was added to 200 parts by weight of water, 1.5 parts by weight of zinc chloride and 0.15 parts by weight of copper chloride were added, heated to 45 ° C, stirred for 1 hour, dialyzed for 3 hours using a dialysis bag with a pore size of 1000 Da, and the dialyzate was dried to obtain an active polysaccharide-Zn / Cu chelate;

[0066] S4. Fermentation: 6 parts by weight of the solid in step S1, 13 parts by weight of the filter residue in step S2, and 4 parts by weight of prebiotics were added to 300 parts by weight of water, sterilized, inoculated with Lactobacillus fermentum LC40 and Lactobacillus paracasei Lpc-37 seed solution, the inoculation amounts were 3v / v% and 1.5v / v%, respectively, at 36°C, 125r / min, fermented and cultured for 42h, filtered, the solid was washed with sterile water, the eluate was collected, concentrated, and a bacterial count of 10 10 -10 11 cfu / mL of concentrated bacterial liquid, and freeze-dried the liquid to obtain the fermentation product;

[0067] S5. Preparation of a probiotic composition for improving mammary glands: 11 parts by weight of the active polysaccharide-Zn / Cu chelate prepared in step S3 and 17 parts by weight of sodium alginate are added to 125 parts by weight of the concentrated bacterial solution prepared in step S4, 3.5 parts by weight of Lactobacillus acidophilus NCFM, 4.5 parts by weight of Bifidobacterium animalis subspecies lactis Bb-12, and 1.5 parts by weight of Lactobacillus rhamnosus GG are added to obtain an aqueous phase, the aqueous phase is added to 500 parts by weight of soybean oil, 2.5 parts by weight of lecithin are added, emulsified at 7000 r / min for 15 minutes, 7 parts by weight of 4wt% calcium chloride solution are added dropwise, solidified at room temperature for 25 minutes, centrifuged, washed, and dried to obtain microcapsules, 17 parts by weight of microcapsules are mixed with 0.7 parts by weight of melatonin, 3 parts by weight of seaweed powder, 4 parts by weight of the fermentation product prepared in step S4, and 3 parts by weight of the propolis active component prepared in step S1, and stirred and mixed for 20 minutes to obtain a probiotic composition for improving mammary glands.

[0068] Comparative Example 1

[0069] Compared with Example 6, the difference is that the low eutectic solvent containing water in step S1 is replaced by an equal amount of water.

[0070] Comparative Example 2

[0071] Compared with Example 6, the difference is that zinc chloride is not added in step S3.

[0072] Comparative Example 3

[0073] Compared with Example 6, the difference is that copper chloride is not added in step S3.

[0074] Comparative Example 4

[0075] Compared with Example 6, the difference is that step S3 is not performed.

[0076] Comparative Example 5

[0077] Compared with Example 6, the difference is that the Lactobacillus fermentum LC40 seed liquid is not inoculated in step S4.

[0078] Comparative Example 6

[0079] Compared with Example 6, the difference is that the seed liquid of Lactobacillus paracasei Lpc-37 is not inoculated in step S4.

[0080] Comparative Example 7

[0081] Compared with Example 6, the difference is that step S4 is not performed.

[0082] Comparative Example 8

[0083] Compared with Example 6, the difference is that no active polysaccharide-Zn / Cu chelate is added in the preparation of microcapsules in step S5.

[0084] Comparative Example 9

[0085] Compared with Example 6, the difference is that no propolis active component is added in step S5.

[0086] Comparative Example 10

[0087] Compared with Example 6, the difference is that no seaweed powder is added in step S5.

[0088] Test Example 1 Gastric Acid Resistance Test

[0089] 0.5 g of the microcapsules prepared in step S5 of Examples 4-6 of the present invention and Comparative Example 8 were added to 9 mL of artificial simulated gastric juice and 9 mL of artificial simulated intestinal juice, respectively, and reacted at 37°C and 100 r / min for 2 h and 3 h, respectively. In addition, an equal amount of microcapsules was first added to 9 mL of artificial simulated gastric juice, reacted at 37°C and 100 r / min for 2 h, centrifuged, and then added to 9 mL of artificial simulated intestinal juice, and continued to react at 37°C and 100 r / min for 3 h. After the reaction, the probiotic cell count was performed. The survival rate and release rate were calculated.

[0090] Survival rate (%) = N t / N0×100%

[0091] Where N t is the concentration of probiotics that survive after incubation in artificial simulated gastric fluid or artificial simulated intestinal fluid in vitro for a certain period of time (cfu / g), and N0 is the original concentration of probiotics added to the artificial simulated gastric fluid or artificial simulated intestinal fluid (cfu / g).

[0092] Release rate (%) = (W0-W t ) / W0×100%

[0093] Where W0 is the initial weight of the sample; W t It is the weight of the sample after incubation for a certain period of time in artificial simulated gastric fluid and artificial simulated intestinal fluid in vitro.

[0094] The results are shown in Table 1.

[0095] Table 1

[0096]

[0097] It can be seen from the above table that the microcapsules prepared in step S5 of Examples 4-6 of the present invention can maintain good integrity in artificial simulated gastric juice, and the release rate is improved in artificial simulated intestinal juice, indicating that the microcapsules are pH responsive and can resist simulated gastric juice well.

[0098] Test Example 2 Therapeutic effect on mastitis mice

[0099] Experimental groups:

[0100] SPF-grade Kunming female mice 3-5 days postpartum were selected and randomly divided into a blank control group, a model group, a positive control group, Example 1-6 groups, and Comparative Example 1-10 groups, with 6 mice in each group. Except for the blank control group, the mice in the other groups were subjected to mastitis modeling after adapting to the environment, and the modeling method was as follows:

[0101] The mice were fasted 3 hours before modeling and the offspring were separated from the mother mice. 4% chloral hydrate was injected into the mother mice intraperitoneally at 0.1 mL / g; after the mice were anesthetized, 50 μL of 0.2 g / L lipopolysaccharide solution was injected into the fourth pair of mammary glands of the mice through the opening of the mammary duct. The mice were killed 24 hours after the injection of lipopolysaccharide solution. The mammary glands of the mice were deformed, swollen, congested or accompanied by necrotic foci. HE staining showed thickening of the wall of the mammary gland alveoli of the mice, and inflammatory infiltration in the mammary gland tissue stroma was observed, which indicated that the modeling of the mice was successful.

[0102] 2 hours after the completion of modeling, the probiotic composition prepared in Examples 1-6 and Comparative Examples 1-10 or the probiotic composition for improving mammary glands was administered orally at a dose of 10 mg / g, the mice in the positive control group were intraperitoneally injected with 5 mg / kg dexamethasone sodium phosphate injection, and the blank control group and the model group were orally administered with an equal volume of normal saline. The treatment was continued for 7 days after modeling.

[0103] Two hours after the drug treatment on the seventh day of the experiment, the mice were killed and the mammary gland tissues were collected, one part for histological observation and the other part for cytokine content determination.

[0104] 1. Histological observation

[0105] HE staining sections of mouse mammary gland tissue were prepared according to the steps, and the degree of mammary gland injury was determined by standard evaluation methods. The injury score represents the severity (0 point, no injury; 1 point, mild injury; 2 points, moderate injury; 3 points, severe injury; 4 points, extremely severe injury).

[0106] The results are shown in Table 2.

[0107] Table 2

[0108]

[0109]

[0110] Note: # means compared with the normal control group, P<0.05; * means compared with the model group, P<0.05.

[0111] It can be seen from the above table that the probiotic compositions or the probiotic compositions for improving mammary glands prepared in Examples 1-6 of the present invention can significantly improve the symptoms of mastitis.

[0112] 2. Cytokine content detection

[0113] ELISA kits were used to detect the levels of TNF-α (tumor cytokine-α), IL-6 (interleukin-6), and MPO (myeloperoxidase) in the mouse mammary gland.

[0114] The results are shown in Table 3.

[0115] Table 3

[0116] Group TNF-α content (ng / L) IL-6 content (ng / L) MPO content (ng / L) Normal control group 157.25±11.59 210.28±22.11 204.52±11.56 Model Group 1224.91±48.51# 846.13±43.65# 577.11±34.27# Positive control group 321.49±21.02* 285.10±17.15* 264.38±7.93* Example 1 346.01±28.36* 310.58±20.58* 278.15±13.22* Example 2 342.17±22.19* 305.67±18.51* 280.11±11.27* Example 3 340.23±20.92* 302.05±21.81* 274.29±14.68* Example 4 278.59±16.88* 265.11±14.28* 245.19±10.32* Example 5 280.14±15.28* 262.01±15.12* 242.38±11.26* Example 6 272.36±18.26* 258.59±13.10* 238.59±13.02* Comparative Example 1 302.51±15.13 289.15±15.19 265.82±14.97 Comparative Example 2 325.29±14.28 299.25±12.39 283.29±12.85 Comparative Example 3 330.18±16.72 297.39±14.02 270.13±14.12 Comparative Example 4 368.26±18.25 318.44±12.11 295.28±15.02 Comparative Example 5 352.11±19.15 310.29±11.05 290.10±12.19 Comparative Example 6 350.38±13.28 313.51±10.92 292.15±11.17 Comparative Example 7 378.53±15.28 332.18±14.28 313.66±14.28 Comparative Example 8 395.67±17.19 346.21±16.88 332.19±16.10 Comparative Example 9 369.83±14.58 325.62±13.09 308.26±15.22 Comparative Example 10 300.25±13.39 285.78±13.36 266.09±15.12

[0117] Note: # means compared with the normal control group, P<0.05; * means compared with the model group, P<0.05.

[0118] Myeloperoxidase activity is a marker of neutrophil function and activation. As shown in the above table, the probiotic composition or the probiotic composition for improving breast prepared in Examples 1-6 of the present invention can significantly reduce inflammatory indicators and reduce myeloperoxidase content.

[0119] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing a probiotic composition for improving mammary glands, characterized in that: The following steps are involved: S1. Extraction of active components of propolis: adding propolis to a low eutectic solvent containing water, extracting by ultrasonic heating, filtering, retaining the solid, and separating and purifying the filtrate with a macroporous resin to obtain active components of propolis; The low eutectic solvent is a mixture of choline chloride and glucose in a molar ratio of 1:1, the water content in the low eutectic solvent containing water is 40-50wt%, the mass ratio of the propolis and the low eutectic solvent containing water is 1:3-5, the power of the ultrasonic heating extraction is 1000-2000W, the heating temperature is 45-55°C, and the time is 1-3h. The macroporous resin is selected from at least one of AB-8, LX-218, XDA-6, D-101, LX-T28 or LX-26. The separation and purification method is to fill the resin to a resin column with a diameter-to-height ratio of 1:5-10, the sample loading amount is 15-25BV, and the adsorption flow rate is 5-7BV / h; after the adsorption is completed, eluted with 3-7BV deionized water, and then eluted with 30-50wt% ethanol solution, the eluate is collected, and dried to obtain the product; S2. Extraction of active polysaccharides: Wash, dry, and crush the astragalus, sponge gourd, and dandelion to obtain a powder, add it to water, heat and boil it for extraction, filter it, and retain the residue. Add ethanol to the filtrate for precipitation, filter it, wash the solid, and dry it to obtain an active polysaccharide; the mass ratio of the astragalus, sponge gourd, and dandelion is 3-5:7-10:2-4, the solid-liquid ratio of the powder and water is 1:5-10g / mL, the heating and boiling extraction time is 3-5h, the ethanol content of the system is 70-80wt%, and the precipitation time is 5-7h; S3. Preparation of active polysaccharide-Zn / Cu chelate: adding the active polysaccharide obtained in step S2 to water, adding zinc salt and copper salt, heating and stirring to react, dialyzing, and drying the dialyzate to obtain active polysaccharide-Zn / Cu chelate; the mass ratio of the active polysaccharide, zinc salt and copper salt is 10-20:1-2:0.1-0.2, the zinc salt is selected from at least one of zinc chloride, zinc sulfate, zinc nitrate and zinc citrate, the copper salt is selected from at least one of copper chloride, copper sulfate and copper nitrate, the temperature of the heating and stirring reaction is 40-50°C, the time is 0.5-1h, the dialysis bag pore size used for dialysis is 500-1000Da, and the dialysis time is 2-4h; S4. fermentation: adding the solid in step S1, the filter residue in step S2, and the prebiotics to water, sterilizing, inoculating Lactobacillus fermentation LC40 and Lactobacillus paracasei Lpc-37 seed liquid, fermenting and culturing, filtering, washing the solid with sterile water, collecting the eluate, concentrating, obtaining a concentrated bacterial liquid, and freeze-drying the liquid to obtain a fermentation product; the mass ratio of the solid in step S1, the filter residue in step S2, the prebiotics and water is 5-7:12-15:3-5:200-400, the prebiotics is selected from at least one of isomaltooligosaccharide, erythritol, oligofructose, and oligogalactose, the inoculation amount of the Lactobacillus fermentation LC40 and Lactobacillus paracasei Lpc-37 seed liquid is 2-4v / v% and 1-2v / v%, respectively, and the bacterial content of the Lactobacillus fermentation LC40 and Lactobacillus paracasei Lpc-37 seed liquid is 10 8 -10 10 cfu / mL, the fermentation culture conditions are 35-38°C, 100-150r / min, fermentation culture for 36-48h, and the bacterial content of the concentrated bacterial solution is 10 10 -10 11 cfu / mL; S5. Preparation of a probiotic composition for improving mammary glands: adding the active polysaccharide-Zn / Cu chelate and sodium alginate obtained in step S3 to the concentrated bacterial solution obtained in step S4, adding Lactobacillus acidophilus NCFM, Bifidobacterium animalis lactis subspecies Bb-12, and Lactobacillus rhamnosus GG to obtain an aqueous phase, adding the aqueous phase to soybean oil, adding lecithin, emulsifying, dropping calcium chloride solution, solidifying at room temperature, centrifuging, washing, and drying to obtain microcapsules, and mixing with melatonin, seaweed powder, the fermentation product obtained in step S4, and the propolis active ingredient obtained in step S1. The components are mixed evenly to prepare a probiotic composition for improving the mammary gland; the mass ratio of the active polysaccharide-Zn / Cu chelate, sodium alginate, concentrated bacterial solution, Lactobacillus acidophilus NCFM, Bifidobacterium animalis lactis subspecies Bb-12, Lactobacillus rhamnosus GG, and lecithin is 10-12:15-20:100-150:2-5:3-6:1-2:2-3, and the mass ratio of the microcapsule, melatonin, seaweed powder, fermentation product, and propolis active component is 15-20:0.5-1:2-4:3-5:2-4.

2. A probiotic composition for improving mammary glands obtained by the preparation method as claimed in claim 1.

Citation Information

Patent Citations

  • Water-soluble pachymaran metal complex and preparing method and application thereof

    CN105859902A

  • Probiotics composition with mammary gland hyperplasia regulating function and application of probiotics composition

    CN106798755A

  • Composition for treating mastitis

    CN110538218A

  • Probiotics for cognitive and mental health

    CN111511378A

  • Preparation method and application of rice bran polysaccharide zinc chelate

    CN113201078A